Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
glioblastoma/hypoxie
Le lien est enregistré dans le presse-papiers
Page 1 de 25 résultats
Antisecretory Factor in Primary Glioblastoma 1
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Glioblastoma (GBM) is the most common primary brain tumor and also has the worst prognosis with a mean survival time below 1 year and a 5-year survival rate of less than 2%.
AF is a 41kilodalton endogenous and essential protein encompassing antisecretory and anti-inflammatory effect. Endogenous AF
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Background:
Osteosarcoma (OS) is the most common type of primary malignant bone tumor in children and adolescents. The overall survival rate is dramatically reduced by the development of metastases, often pulmonary. Solid malignant tumors, such as OS, often develop a hypoxic microenvironment, which
IA Carboplatin + Radiotherapy in Relapsing GBM
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
A phase II study in relapsing glioblastomas (GBM) using concurrent intraarterial carboplatin chemoradiation therapy.
BACKGROUND - Contemporary treatment of GBM brain tumors involves a first-line treatment in which the patient receives a surgical procedure followed by a combination of radiation and
Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
PRIMARY OBJECTIVES:
I. To estimate the efficacy of HIF-2 alpha inhibitor PT2385 (PT2385) as measured by radiographic response rate (by Response Assessment in Neuro-Oncology, RANO, criteria) in patients with recurrent glioblastoma.
SECONDARY OBJECTIVES:
I. To estimate the efficacy of PT2385 as
Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND Radiation Necrosis: Stereotactic radiosurgery has become integral in treatment of brain tumors and arteriovenous malformations (AVM). In up to 10% of cases, this can lead to radiation necrosis (RN) with significant surrounding vasogenic edema and mass effect. Medical treatment for RN
Tumor Hypoxia With HX4 PET in Several Diseases
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Rationale: Non-invasive imaging of hypoxia with the aid of PET-scans could help to select the patients having a hypoxic tumor, who could be treated with specific anti-hypoxic treatments. The added value of additional anti-hypoxic treatments depends on the presence of hypoxia and adequate patient
Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Glioma is the most frequent malignant primary brain tumor and remains a lethal disease with a dismal prognosis. Glioblastoma (GBM) accounts approximately 50% of all glioma and among these tumors, are the most malignant. GBM are characterized by a higher cellular density and by the ample existence of
The Addition of Chloroquine to Chemoradiation for Glioblastoma,
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
This study is a multi-centre randomized controlled, open label, phase II trial for patients with de-novo GBM.
Eligible patients will be randomized between arm A and arm B:
Arm A (standard): Radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 30
The Addition of Chloroquine to Chemoradiation for Glioblastoma
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
This trial has been designed as an open label, single center combination phase I trial. The primary objective is to determine the maximum tolerated dose (MTD) for chloroquine (CQ) in combination with concurrent radiotherapy with daily temozolomide in patients with a newly diagnosed GBM.
Eligible
qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
We propose a study to demonstrate quantitative oxygen saturation estimation in GBM is feasible with qBOLD and it correlates with established histopathological markers of hypoxia and angiogenesis, and targeted intraoperative oxygen measurement.
All patients will undergo surgery as part of their
Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Glioblastomas are tumors with poor prognosis. The treatment of recurrent glioblastoma after a standard first-line treatment is not clearly codified, however, many results in the literature show the benefit of bevacizumab (anti- angiogenic therapy) and it is often proposed in this indication . Tissue
Disease Progression and Treatment-induced Alterations in Glioblastoma
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Objectives of the project:
The aim of this study is to analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance in matched pre- and post-therapeutic glioblastoma samples.
The following primary aims will be addressed:
1. Morphological
A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
1.1 Primary Aim: To describe MRI response rate as regards edema and enhancement of glioblastoma and radiation- related brain enhancement when treated with subcutaneous (SQ) bevacizumab daily. See section 11 for detail on response assessment.
1.2 Secondary Aims: 1.2.1 To characterize toxicities of SQ
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
